NCT07294664 2026-04-16
PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2 Recruiting
Clinical Trials
10 trialsNCT05905887 2026-04-07
Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor
Asan Medical Center
Phase 2 Recruiting
NCT06145308 2026-04-02
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Peking Union Medical College
Phase 2 Recruiting
NCT07479732 2026-03-18
Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma
Peking University People's Hospital
Phase 1/2 Recruiting
NCT06346392 2026-03-09
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
AstraZeneca
Phase 3 Recruiting
NCT07033819 2026-02-27
Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT05027386 2026-02-05
Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study.
Sun Yat-sen University
Phase 1/2 Recruiting
NCT05139095 2026-02-05
Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT04342910 2026-01-20
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Recruiting
NCT07353684 2026-01-20
Adebrelimab, Apatinib & SOX for Conversion Therapy in Advanced Gastric/GEJ Cancer
Beijing Friendship Hospital
Phase 2 Recruiting